Key Points
- Director Oliver Rolf Baumann purchased 50,000 Veraxa Biotech shares at an average price of $1.50, investing $75,000. His holdings rose 0.87% to 5,773,618 shares.
- VRXA opened at $1.35, near its 52-week low of $1.32 and far below its 52-week high of $27.36.
- Wall Street Zen recently upgraded Veraxa Biotech from “sell” to “hold.”
Veraxa Biotech Holding AG (NASDAQ:VRXA - Get Free Report) Director Oliver Rolf Baumann acquired 50,000 shares of the firm's stock in a transaction on Thursday, August 27th. The stock was purchased at an average cost of $1.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director owned 5,773,618 shares in the company, valued at approximately $8,660,427. This represents a 0.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Veraxa Biotech Stock Performance
VRXA stock opened at $1.35 on Tuesday. Veraxa Biotech Holding AG has a fifty-two week low of $1.32 and a fifty-two week high of $27.36.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a "sell" rating to a "hold" rating in a research note on Monday.
View Our Latest Stock Report on VRXA
Veraxa Biotech Company Profile
(
Get Free Report)
Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.
The company's work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.
Publicly available information about Veraxa Biotech's corporate history, geographic operations and leadership is limited.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
